February 23, 2024 - R&D funding: In 2023, global funding of biopharmaceutical research and development increased to $72Bn, up from $61Bn in 2022. In the same period, M&A activity jumped to $140Bn from $78Bn in 2022, while the median deal value fell for the second ...

September 9, 2025 - Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output.

Report Summary: Biopharmaceutical R&D remained resilient in 2025, with investment and dealmaking increasingly concentrated in high value science, emerging biopharma, and China linked activity.

February 9, 2023 - Cross-border data transfers are critical to the research, development, and delivery of new biopharmaceutical medicines to prevent and treat medical conditions and improve patients’ health. Cross-border Data Analytics and R&D Collaboration. Cross-border data analytics can help speed the early identification of potentially useful drug candidates, shortening discovery timelines from years to months.

September 16, 2024 - Biopharmaceutical companies are investing in R&D on an immense, global scale. The study indicates that global biopharmaceutical R&D investment is significant, totaling $276 billion across 4,191 global companies in 2021.

This report from the IQVIA Institute - Global Trends in R&D 2025: Progress in Recapturing Momentum in Biopharma Innovation - assesses the trends in R&D funding, clinical trial activity, and new drug approvals and launches. It also examines the efficiency and productivity of clinical development, using a refreshed Clinical Program Productivity Index, while also providing insights on contributing factors and enablers.

May 5, 2024 - full private biopharmaceutical R&D ecosystem · Global R&D volume · • · 2021 global R&D investment (Figure 2) was $276 billion across 4191 global companies, with total net revenues of $1022 billion across 583 companies. • · Of total R&D investment, 583 commercial-stage and 3608 ...

August 12, 2024 - Skip to content

August 6, 2024 - Research and development (R&D) investment in the biopharmaceutical industry drives the discovery of new drugs to address unmet medical needs and improve patient outcomes.

Pharmaceutical R&D spending worldwide will exceed 300 billion U.S. dollars in the upcoming years. The U.S. is the global leader in life sciences research.

Detail on the measurement of R&D investment in each population is provided in Supplementary · Boxes 4–7. We also conducted sensitivity analyses to assess the impact of IPR&D expense and · alternative measurement approaches for public development-stage companies. ... Fig. 1 | 2021 global biopharmaceutical ecosystem R&D investment.

2 weeks ago - The United States has one of the world’s most supportive domestic environments for the development and commercialization of pharmaceuticals with minimal market barriers. The United States is one of the largest markets for biopharmaceuticals and is the world leader in biopharmaceutical R&D.

We first discuss the empirical evidence on the extent and nature of this process. We then examine whether this global spread of biopharmaceutical R&D supports or hurts host country knowledge activity. We conclude that foreign knowledge discovery by biopharmaceutical companies tends to complement, ...

May 20, 2026 - Leading 15 mechanisms of action in R&D pipeline drugs worldwide by number of active compounds as of 2025 ... Average cost to develop a compound for biopharma companies from 2013 to 2024 (in billion U.S. dollars) Average peak sales forecast per new biopharmaceutical asset 2013-2024 · Average peak sales forecast per new biopharmaceutical asset 2013-2024 · Projected average peak sales for each new biopharmaceutical asset from 2013 to 2024 (in million U.S. dollars) ... Global ...

May 6, 2022 - Yet in the same period, success rates, speed, and productivity for clinical development have remained stubbornly flat despite global R&D investments increasing sharply—with US R&D spend doubling from $40 billion to $80 billion between 2001 and 20194Annual spending by PhRMA member firms, as reported in “Research and development in the pharmaceutical industry,” Congressional Budget Office, April 2021.

May 19, 2026 - In the United States, the pace of biopharmaceutical innovation has enjoyed remarkable growth over the last decade. New drug approvals by the Food and Drug Administration increased from 209 between 2000–2008 to 302 between 2009–2017—a 44.5 percent surge. Furthermore, U.S. firms filed nearly 38 percent of global biotechnology patents from 2015–2020, bolstering the U.S.

Development Goals (SDGs). ... USD 1,838 billion. ... EXECUTIVE SUMMARY................................................................................................................9 · Biopharmaceutical Innovation and Global Public Health............................................................... 9 · The Role ...

April 21, 2026 - The biopharmaceuticals market is growing rapidly, driven by advances in biologics, personalized medicine, and gene therapy. Innovations in monoclonal antibodies, vaccines, and cell therapies are transforming treatments. Demand for biologics in chronic and rare diseases is rising globally, boosting ...

July 10, 2025 - The biopharmaceutical industry appears to be entering a dynamic and potentially pivotal moment. Along with regulatory changes that often come with a new administration, many top-selling drugs will lose patent protection over the next five years, potentially affecting more than $300 billion in sales between 2026 and 2030.1 Moreover, increasing margin pressure and changing dynamics related to new drug launches could alter the playing field.2 Despite these factors, some research indicates that the global biopharma market could continue to grow steadily through 2030.3

The European Investment Bank-backed investment establishes a new single-use GMP facility with which Icosagen can support complex protein therapeutics from early discovery through phase 1/2 clinical manufacturing. ... The biopharmaceutical landscape grows increasingly complex, and competition for experienced engineering talent has intensified accordingly.